Eric Devroe insider trades
Open-market stock purchases and sales by Eric Devroe, Chief Operating Officer at Acrivon Therapeutics, Inc, from SEC Form 4 filings since Nov 14, 2022.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -20%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| May 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $1.2K |
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| Feb 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $1.2K |
| Jan 13, 2026 | ACRV Acrivon Therapeutics, Inc | Bought | $17.2K |
| Nov 14, 2025 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $1.4K |
Companies traded
- ACRV Acrivon Therapeutics, Inc: 1 buy, last May 18, 2026